FGFR1 and T-cell acute lymphoblastic leukemia: Despite the emergence of drug resistance, precision treatment with a combined synergistic effect of mTOR and fibroblast growth factor receptor 1 (FGFR1) inhibitors is promising for T-cell acute lymphoblastic leukemia (T-ALL).